Neogen Corp
NEOG Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 26, 2026
$12.21
KIRA · Stoqly’s AI analyst, in plain words
- Neogen Corp had $870M of revenue in fiscal 2026, down 2.7% on the year before. Over five years, revenue changed +13.2% a year on average.
- Its operating margin was −2.5%, up 116.1 pts: of every 100 in sales, about −2 is left after running the business.
- Neogen Corp lost $7.9M in fiscal 2026.
- Free cash flow was $31.9M in fiscal 2026, 3.7% of revenue.
- Neogen Corp owes $608M more than it holds in cash, about 6.4 years of operating profit.
Market cap
$2.7B
P/E
—
Revenue
$870M
Net income
−$7.9M
Free cash flow
$31.9M
Operating margin
−2.5%
Neogen Corp in 30 seconds · fiscal 2026
Are sales growing?
−2.7%
No. Sales fell 2.7% last year.
Does it make a profit?
−0.9%
No. It lost money last year.
Does profit turn into cash?
3.7%
Partly. 3.7% of sales ends up as free cash.
Is debt under control?
6.4x
Heavy. Repaying its debt would take 6.4 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Neogen Corp does
No business description yet.
- Fiscal year ends
- May 31, 2026
- Latest annual report
- 10-K · Jul 30, 2026
- Legal name
- NEOGEN CORP
- CIK
- 0000711377
Neogen Corp · NEOG
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $527M | $822M | $924M | $895M | $870M |
| Revenue growth | 12.5% | 56.0% | 12.4% | −3.2% | −2.7% |
| Gross margin | 46.1% | 49.4% | 50.2% | 47.1% | 46.9% |
| Operating margin | 11.1% | 4.6% | 6.3% | −118.6% | −2.5% |
| Net income | $48.3M | −$22.9M | −$9.4M | −$1.1B | −$7.9M |
| Net margin | 9.2% | −2.8% | −1.0% | −122.1% | −0.9% |
| Diluted EPS | $0.45 | −$0.12 | −$0.04 | −$5.03 | −$0.04 |
| Cash | |||||
| Cash from operations | $68.0M | $41.0M | $35.3M | $58.2M | $83.2M |
| Capital expenditure | $24.4M | $65.8M | $111M | $105M | $51.3M |
| Free cash flow | $43.6M | −$24.7M | −$76.1M | −$46.4M | $31.9M |
| FCF margin | 8.3% | −3.0% | −8.2% | −5.2% | 3.7% |
| Share count change | 0.8% | 74.9% | 14.6% | 0.2% | 0.3% |
| Debt and strength | |||||
| Cash and short-term investments | $381M | $246M | $171M | $129M | $186M |
| Debt incl. finance leases | $0.0M | $1.8B | $893M | $897M | $794M |
| Shareholders' equity | $887M | $3.1B | $3.1B | $2.1B | $2.1B |
| Net debt / EBITDA | −4.6x | 12.2x | 4.1x | — | 6.4x |
| Current ratio | 8.1x | 4.0x | 3.8x | 3.3x | 3.8x |
| Interest coverage | — | 1.4x | 1.4x | −27.8x | −0.9x |
| Returns and quality | |||||
| Return on capital | 9.3% | 0.6% | 1.2% | −29.6% | −0.6% |
| Return on equity | 5.6% | −1.1% | −0.3% | −41.9% | −0.4% |
| Return on tangible equity | 7.4% | — | — | — | — |
| Piotroski F-score | 5 | 3 | 6 | 3 | 6 |
| Altman Z'' | 14.8 | 3.4 | 3.5 | −0.2 | 2.1 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Neogen Corp · NEOG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.21 a share, the company is worth $2.7B.
Source: SEC EDGAR XBRL filings (CIK 0000711377). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.